BiVictriX Therapeutics announced today that it has received encouraging final data from a second in vivo efficacy study of its lead clinical candidate, BVX001. This promising antibody has shown great potential for treating acute myeloid leukemia.
According to the company’s statement, at day 28 of the study, BVX001 demonstrated highly statistically-significant tumor regressions of 97%. These results build upon the positive interim data from the same study, which showed tumor regressions of 89% at day 18.
In addition to the positive data, BiVictriX Therapeutics informed that the U.S. Patent and Trademark Office has issued a notice of allowance for an initial broad patent for BVX001 in the United States. The company expects that the patent claims will be granted within the coming months.
The objective of the study was to assess the anti-tumor responses of BVX001, which was dosed twice weekly, in a more challenging setting where tumors were administered at a large size. This is an important step towards advancing BVX001 into human trials.
“We are pleased with the results of this study, which will contribute to the comprehensive preclinical data package we are building,” said Chief Executive Tiffany Thorn. She added, “These findings further support our confidence in BVX001 as a potential treatment for acute myeloid leukemia.”